Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. Mesothelioma 67%
3. entrectinib 63%
4. Malignant Mesothelioma 57%
5. Neoplasms 38%
6. Oncolytic Virotherapy 30%
7. Eukaryotic Initiation Factor-4F 29%
8. Oncolytic Viruses 28%
9. Vesicular Stomatitis 22%
10. Viruses 22%
11. Therapeutics 21%
12. Acridines 19%
13. Eukaryotic Initiation Factor-4E 19%
14. Lung Neoplasms 18%
15. Eukaryotic Initiation Factors 17%
16. Topoisomerase II Inhibitors 17%
17. Pemetrexed 16%
18. Immunotherapy 16%
19. Interferons 16%
20. Measles virus 15%
21. Interleukin-15 15%
22. Antisense Oligonucleotides 14%
23. Survival 14%
24. sitravatinib 14%
25. Protein Biosynthesis 14%
26. Safety 13%
27. Progression-Free Survival 13%
28. simocyclinone D8 13%
29. Type II DNA Topoisomerase 12%
30. 14-O-phosphonooxymethyltriptolide 12%
31. ALT-803 12%
32. Growth 12%
33. Head and Neck Neoplasms 12%
34. Drug Therapy 12%
35. Cell Proliferation 12%
36. mocetinostat 11%
37. Apoptosis 11%
38. gemcitabine 10%
39. Phosphorylation 10%
40. Cell Line 10%
41. avelumab 10%
42. durvalumab 10%
43. Aminacrine 10%
44. tropomyosin kinase 10%
45. INCB018424 10%
46. Emotions 9%
47. Outpatients 9%
48. Prodrugs 9%